Skip to content
Back to the Guavy Wire
Stocks

Moderna's Cancer Vaccine Shows Promise but Stock Drops Sharply

Instruments
MRK
Share

Moderna's experimental cancer vaccine, intismeran autogene, showed promising results in a Phase 3 trial, yet the stock plummeted more than 25% on the day of the announcement. The vaccine, developed in partnership with Merck, reduced the risk of recurrence or death by 42% when combined with Merck's Keytruda, compared to Keytruda alone. Despite this positive outcome, investors had anticipated even better results, leading to the sharp decline in Moderna's stock price.

The trial results were leaked ahead of their scheduled presentation at the European Society for Medical Oncology (ESMO) Congress. Analysts had hoped for a hazard ratio below 0.60, which would indicate a reduction in risk of more than 40%. The actual result came in at 0.58, narrowly meeting expectations but still falling short of the market's high hopes. However, the full conference presentation revealed a more encouraging picture, with the vaccine reducing the risk of recurrence or death by 58% based on outcomes six months or more after the initial treatment.

Beyond melanoma, Moderna and Merck are exploring the potential of intismeran for other types of cancer, including renal cell carcinoma, bladder cancer, and non-small cell lung cancer. Preliminary data from a study on pancreatic cancer showed 55% of patients remaining relapse-free after 17 months of follow-up. Despite these developments, the vaccine still requires FDA approval, and its effectiveness in other cancer types has yet to be proven.

Moderna's stock trades at a price-to-sales (P/S) ratio of about 35 times, reflecting high expectations for future growth. Merck, on the other hand, trades at a forward price-to-earnings (P/E) ratio of about 16. Analysts suggest that investors may be focusing too much on one trial result and not on Moderna's longer-term business potential.

More on Stocks